{"name":"Intercept Pharmaceuticals","slug":"intercept","ticker":"ICPT","exchange":"NASDAQ","domain":"interceptpharma.com","description":"Intercept Pharmaceuticals, Inc. is an American biopharmaceutical company incorporated in 2002, focusing on the development of novel synthetic bile acid analogs to treat chronic liver diseases, such as primary biliary cirrhosis (PBC) now called primary biliary cholangitis, non-alcoholic fatty liver disease, cirrhosis, portal hypertension, primary sclerosing cholangitis and also the intestinal disorder, bile acid diarrhea.","hq":"Morristown, NJ","founded":0,"employees":"","ceo":"Jerry Durso","sector":"Liver Disease","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$1.4B","metrics":{"revenue":450000000,"revenueGrowth":247.5,"grossMargin":0,"rdSpend":176639000,"netIncome":221816000,"cash":553711000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2017"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2034-06-01","label":"Ocaliva patent cliff ($1.4B at risk)","drug":"Ocaliva","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Intercept Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Intercept Pharmaceuticals reported its financial results for the fourth quarter and full year 2023, with revenue of $143.8 million and a net loss of $134.4 million.","drugName":"","sentiment":"neutral"},{"date":"2023-11-07","type":"deal","headline":"Intercept Pharmaceuticals Announces Collaboration with Gilead Sciences to Develop and Commercialize Ocaliva for Primary Sclerosing Cholangitis","summary":"Intercept Pharmaceuticals announced a collaboration with Gilead Sciences to develop and commercialize Ocaliva for the treatment of primary sclerosing cholangitis (PSC).","drugName":"","sentiment":"positive"},{"date":"2023-08-01","type":"regulatory","headline":"FDA Approves Ocaliva for the Treatment of Primary Sclerosing Cholangitis","summary":"The FDA approved Ocaliva (obeticholic acid) for the treatment of primary sclerosing cholangitis (PSC).","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxOWk5MUTVPMWF4Q3hhWTl0UmZtTnVSQVFlVm01SXNMbWRCVjB5eHc1V2tIdjFxUi02bThiX0g0N2pIZEZBNXdTbElkaWdvSkNqTXpCZG00RWNVMGJSM1NaUGRQRXo4VG1DUW1JZ1JfLVlLdk9yR1E5UHFZUDA4TC1NTUVhUm5KVnA5M0R5bzVnS1Z2WV9uanJCRFpCa3g?oc=5","date":"2023-10-11","type":"pipeline","source":"Yahoo Finance","summary":"Intercept Pharmaceuticals (NASDAQ:ICPT) shareholders have endured a 83% loss from investing in the stock five years ago - Yahoo Finance","headline":"Intercept Pharmaceuticals (NASDAQ:ICPT) shareholders have endured a 83% loss from investing in the stock five years ago","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3wJBVV95cUxQVDVtMmtTd3pNVjJuS1A1dzJqMHI3RjdlTWt1Mm9GajhoQzV4bU81dEZ4dUU5VkpXVVNicHl1X1Y4ckg1NjhoeWZLUlNzVHJJWXNkUGFrY3NRZW1CLU1VMTZJNTY3aTVqcGlOZWFSNnFnSGtCVk1aSEdDWktqNkFuRGxNMnQ3cFZPV2tvbTkzWm1samdzQXZ1eE5oM3hHN3JFclMtWkJLUmZyR3lBZF9paFYzVUptYjVUN1Z3MHBaeHdwQ0daY09SVEF2S2V0T2dlVnNJRy1UNUEydEUwNjh2NEdySWRzYnRiMkN4dHZINEZpX3ZxbVduSGhaT01FUUFzRHNpZk5YZU5oOFU0VXJ5OW1seDg5Rm51UV9PN2VsTWVMMEE2aG5VTGpSMHB4dXJhNUJ0d1JlM2x1Ql9Ob0o0R2tmSlJWR1ctanQ4UHFmRnpGUDBuNElqN1gwVDB1VHc?oc=5","date":"2023-09-26","type":"deal","source":"globenewswire.com","summary":"Alfasigma to Acquire Intercept Pharmaceuticals for $19.00 - globenewswire.com","headline":"Alfasigma to Acquire Intercept Pharmaceuticals for $19.00","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxPWjY5UHVxdnk5M2h6bzkxVUpBTzR0alNzUjlCc0dhLTBtWXVQX3gxYlp3X2U2cWxQN3lUd2E5b0FVQUdIbDhuOUR3R3FUMkpuR1kwMDJaNWlqRUtoS2J6RklILTZYWG9xUnZSNzBLWVlzbngwamROczVoQzdxZi12TWdLX01NUk9iUkhSUl9IRi1iTkdGV2NKX19HU0NzNzFYRGxQcEtVYUtBMzJHTzFF?oc=5","date":"2023-09-26","type":"deal","source":"Seeking Alpha","summary":"Intercept: Alfasigma Pays Premium For M&A Deal That Suits All Parties (NASDAQ:ICPT) - Seeking Alpha","headline":"Intercept: Alfasigma Pays Premium For M&A Deal That Suits All Parties (NASDAQ:ICPT)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiywFBVV95cUxNWmJBOF9pNXhDM04xb2hhUDBGUi13dklXQjVTcW9wajlKNGF6czk1ZWpHU0RodTRXWTU1Ykc2ZklWWmo4QzBmQWJhVm1FLXpvdy1UQ2VZbUpvYmlDTkdsTGQ2Y2dhbzNma2VFSVhpS05SdkVLR3NsSFpSNDZsXzhFOFFaZVB4NmlXbVo4N1pUX21GWktuZVhkZFNJeFIxMndac1VTdkh5cWlYX0t0cTNIdk1DbFlOUGZiZEVWMGZ1dG5jNlNLTDRWSGlvWQ?oc=5","date":"2023-06-22","type":"regulatory","source":"Reuters","summary":"FDA declines to approve Intercept's fatty liver disease drug - Reuters","headline":"FDA declines to approve Intercept's fatty liver disease drug","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMicEFVX3lxTE1WQWRBUUhocXdDcEdQUUR6SHdxUTBWSFhFWVgycFRyak0tN1NSRjFjY0VuOTlFem9qQjJ2azFfRzMzVW5NemVkSEF4VGNHMWlaUVFZTlhTZkdUZlNNLUZIT0tBNG5aMllxRUJ4cjRxT2Y?oc=5","date":"2023-04-19","type":"earnings","source":"Investopedia","summary":"Top Biotech Stocks for Q2 2023 - Investopedia","headline":"Top Biotech Stocks for Q2 2023","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi9wFBVV95cUxNOTNfNW1uaC1McGJuWEdCdEZheDhiWVYyakxFTF9qV3Q5WTFOUy1FRkVwbVZZMG85dkxGTEdlbmFKel92bF9Xbk1PT0hYaUZHSUVBR3hPWWpValRQVnk2alktSzdRSUMzYkFjVzhwUXJOUEZmNXdVNnhydHNXRFJSYW1RX0FaTFJWWHlrczhydF9MRjYyZGtsZlhzT1N2OGJDbEdReUtSWFFMV0RNOWN5LUduMTBlUWM2WkViTFhOWkFBRXQ5ZElpRVo3UjdEQ29uUXY5U1R1cXliVjJLU01iWm1xQTk0bWkwX2ZiSXF5WlhnRWhjOHFR?oc=5","date":"2020-08-21","type":"trial","source":"StreetInsider","summary":"Intercept Pharma (ICPT) to Present New NASH and PBC Data at Digital International Liver Congress 2020 - StreetInsider","headline":"Intercept Pharma (ICPT) to Present New NASH and PBC Data at Digital International Liver Congress 2020","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxQLWxqMUNHb0tmZjhMWVFubU9yb3puWEJBN2ZjRjhHeVRiMXc5ZUgzTnp0TXpfQlA2WHp0UXRmYnE0RERUZU12TGVUNmlUMDkyNS1HanNwQmg4T0NfMy1WZ19uY0pETFV4Mkh1LUdWcUFEeDBXY2lSOEdLSVVtU3pDcGpVQkRCejJVQV9IRWMtVk5wQ2F6ZmVYcGNFVmJOZw?oc=5","date":"2019-02-20","type":"pipeline","source":"The Motley Fool","summary":"Here's Why Intercept Pharmaceuticals Changed Course Today - The Motley Fool","headline":"Here's Why Intercept Pharmaceuticals Changed Course Today","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMib0FVX3lxTE41WU0zOWhvWG9sV2xDVVBMT0x6TlBrRnQzY2M3eEdIcHcyM3pjakljMkJyZzNqY3lKWUNwSF8xalhoZ1FqSDhfSWxtMnRQYWlDUU5uY1hLZi1SdS1zYkNxTU5wR2NtYzh6Wk9RbzU2cw?oc=5","date":"2016-03-25","type":"pipeline","source":"fortune.com","summary":"The 7 Blockbuster Drugs to Watch For This Year - fortune.com","headline":"The 7 Blockbuster Drugs to Watch For This Year","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxOMDhvRmptNmRyc1lTWFk5UFhQMjFmazlrcGJxTzlSYkZmclhmYzRUdThKM0tMSU43dXMzV19wM2phOE1lU09QLXJDYmFaUVU0ME1aNDFpdE5KTUdrZ0dpeXRSOG9QSm9kSmt4eEhFaXNrcmxMWVFZUy1aOG1OeGhfLWw5alllOTRicnh0b21Hcnh3cVFaTnc?oc=5","date":"2015-09-01","type":"pipeline","source":"Barron's","summary":"Intercept Pharma Could Be Bought for $493 a Share - Barron's","headline":"Intercept Pharma Could Be Bought for $493 a Share - Barron's","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiWkFVX3lxTE5MdXlQYmhlVDJCS3F3R3ZKMy1SSWNFbXIyZTlRM3lXcms1MnR3MWFJTDRHRGJoS3hGeFlQQW9sOC1wMGxuMFpqM3V6UDRxdnJCTjhFXzlWZlNFUQ?oc=5","date":"2015-06-04","type":"pipeline","source":"MarketBeat","summary":"Intercept Pharmaceuticals (ICPT) Stock Price, News & Analysis $ICPT - MarketBeat","headline":"Intercept Pharmaceuticals (ICPT) Stock Price, News & Analysis $ICPT","sentiment":"neutral"}],"patents":[{"drugName":"Ocaliva","drugSlug":"obeticholic-acid","patentNumber":"","type":"Patent Cliff","expiryDate":"2034-06-01","territory":"US","annualRevenue":1400000000}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Gilead Sciences","Madrigal Pharmaceuticals","Madrigal Pharmaceuticals"],"therapeuticFocus":["Liver Diseases"],"financials":{"source":"sec_edgar+yahoo","revenue":130956000,"revenuePeriod":"2017-12-31","revenueHistory":[{"value":130956000,"period":"2017-12-31"},{"value":37687000,"period":"2017-12-31"},{"value":41334000,"period":"2017-09-30"},{"value":30887000,"period":"2017-06-30"},{"value":21048000,"period":"2017-03-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":176639000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":221816000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":553711000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}